NO. 2682—P. 3——

Application Ser. No.: 10/613,588

Filing Date: July 3, 2003 Examiner: Desai, Rita J.

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

- 1. -2. (canceled)
- 3. (currently amended) A compound of the formula 1-as-claimed in claim 1, wherein the compound of the formula I is selected from the group consisting of:
 - 5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,
 - 3-methyl-5-(2-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
 - 3-methyl-5-(3-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
 - 3-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
 - 1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
 - 5-phenyl-3-trifluoromethyl-1H-pyrazolo[4,31c]isoquinoline,
 - 1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
 - 1,3-dimethyl-5-(2,6-difluorophenyl)-1H-pyrázolo[4,3-c]-isoquinoline,
 - 1-benzyi-5-cyclohexyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 1-benzyl-5-naphthyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 5-methoxymethyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 7-methoxycarbonyl-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 7-methoxycarbonyl-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 7-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,
 - 7-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 6-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,
 - 6-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
 - 8-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,

USAV2003/0110 US NP

Application Ser. No.: 10/613,588

Filing Date: July 3, 2003 Examiner: Desai, Rita J.

8-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline, 1,3-dimethyl-5-(3-methyl-thiophen-2-yl)-1H-pyrazolo[4,3-c]-isoquinoline, 3-methyl-5-phenyl-9-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline, 3-methyl-5-pyridin-2-yl-9-trifluoromethyl-1H-pyrazolo[4,3-c]-isoquinoline, and 3-methyl-5-(2,3,4,5,6-pentafluoro-phenyl)-1H-pyrazolo[4,3-c]-isoquinoline.

- 4. (canceled)
- 5. (withdrawn-currently amended) A pharmaceutical composition comprising a therapeutically effective content of at least one compound of the formula-I as claimed in claim 1 claim 3 together with a pharmaceutically suitable carrier optionally in combination with a suitable additive, other active compounds and auxiliary substances.
- 6. (withdrawn-currently amended) A method of treating a disease condition associated with the increased activity of NIK selected from the group consisting of osteoarthritis, rheumatoid arthritis, asthma, irritable bowel disease, atherosclerosis, rejection reactions on the part of the body against a transplanted organ and rejection reactions on the part of the transplanted organ against the body, comprising administering to a patient suffering from said disease condition a therapeutically effective amount of a compound according to claim 1 claim 3.
- 7. 8. (canceled)
- 9. (withdrawn) The method as claimed in claim 6; wherein the disease condition is caused due to an inflammatory component.
- 10. 18. (canceled)

USAV2003/0110 US NP

Application Ser. No.: 10/613,588

Filing Date: July 3, 2003 Examiner: Desai, Rita J.

- 19. (withdrawn-currently amended) The method as claimed in claim-18 claim 6, wherein the disease condition is multiple sclerosis osteoarthritis.
- 20. (withdrawn-currently amended) The method as claimed in claim 18 claim 6, wherein the disease condition is atherosclerosis.
- 21. (withdrawn-currently amended) The method as claimed in claim-18 claim 6, wherein the disease condition is inflammatory irritable bowel disease.
- 22. (withdrawn-currently amended) The method as claimed in claim 18 claim 6. wherein the disease condition is Alzheimer's disease rheumatoid arthritis.
- 23. (withdrawn-currently amended) The method as claimed in claim 18 claim 6. wherein the disease condition is stroke rejection reactions on the part of the body against a transplanted organ.
- 24. (withdrawn-currently amended) The method as claimed in claim 18 claim 6, wherein the disease condition is diabetes rejection reactions on the part of the transplanted organ against the body.